EUVIMEDEUVIMED entdecken
Crossref

Exploration of thiazolidine‐2,4‐diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations

Nada A A M Aziz, Riham F George iD, Khaled El-Adl iD, Walaa R Mahmoud iD

Archiv der Pharmazie · 2023-03 · 356 (3)

DOI: 10.1002/ardp.202200465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 20.11.2022. Verfasst von Nada A A M Aziz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As dual EGFR and VEGFR‐2 inhibitors, 22 innovative thiazolidine‐2,4‐diones were modeled, constructed, and measured for their anticancer performance versus four human neoplasms HCT‐116, MCF‐7, A549, and HepG2. Molecular docking and MD simulation were performed to inspect the binding technique of the proffered congeners with the EGFR and VEGFR‐2 receptors. Evidence realized thanks to the docking inquests was vastly consistent together with that detected through the biological screening. Structures 14a and 14g emerged as the most active compounds toward HCT116 (IC 50 = 6.01 and 7.44 µM), MCF‐7 (IC 50 = 5.77 and 7.23 µM), A549 (IC 50 = 5.35 and 5.47 µM) and HepG2 (IC 50 = 3.55 and 3.85 µM) tumefaction cells. Compounds 14a and 14g exhibited higher events than sorafenib (IC 50 = 5.05, 5.58, 4.04, and 4.00 µM) against HepG2 instead subordinate incidents concerning A549, MCF‐7, and HCT116, parallelly. Nevertheless, these compounds signified weightier performance than erlotinib (IC 50 = 13.91, 8.20, 5.49, 7.73, and µM), with respect to the four cell lines. Compounds having the best activity against the four cell lines, 12a–f , 13a–d , and 14a–g were chosen to appraise their in vitro VEGFR‐2 and EGFR T790M inhibiting activities. The best results were for compounds 14a and 14g compared to sorafenib and erlotinib, respectively, with IC 50 values of 0.74 and 0.78 µM and 0.12 and 0.14 µM, respectively. Moreover, 13d , 14a , and 14g showed an adequate in silico calculated ADMET profile. The current investigation presents novel candidates for future optimization to construct mightier and eclectic binary VEGFR‐2/EGFR T790M restrainers with higher antitumor effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLung NeoplasmsHumansSorafenibStructure-Activity RelationshipErlotinib HydrochlorideErbB ReceptorsThiazolidinesVascular Endothelial Growth Factor Receptor-2Tyrosine Kinase InhibitorsCell ProliferationMolecular Docking SimulationProtein Kinase InhibitorsDrug Screening Assays, AntitumorMutationMolecular StructureDrug Design

Stichwörter der Autor:innen

antiproliferative agentsdual inhibition of VEGFR-2/EGFRT790Mmolecular dockingthiazolidine-2,4-diones

Substanzen

SorafenibErlotinib HydrochlorideErbB ReceptorsAntineoplastic AgentsThiazolidinesVascular Endothelial Growth Factor Receptor-2Tyrosine Kinase InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Heliopolis University for Sustainable Development, Cairo, Egypt.
  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.

ORCID-Profile: Riham F George, Khaled El-Adl, Walaa R Mahmoud

Zitieren

APA

Aziz, N. A. A. M., George, R. F., El-Adl, K., & Mahmoud, W. R. (2023). Exploration of thiazolidine‐2,4‐diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations. Archiv der Pharmazie, 356(3). https://doi.org/10.1002/ardp.202200465

Vancouver

Aziz NAAM, George RF, El-Adl K, Mahmoud WR. Exploration of thiazolidine‐2,4‐diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations. Archiv der Pharmazie. 2023;356(3). doi:10.1002/ardp.202200465

BibTeX
@article{Aziz2023,
  author = {Aziz, Nada A A M and George, Riham F and El-Adl, Khaled and Mahmoud, Walaa R},
  title = {Exploration of thiazolidine‐2,4‐diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations},
  journal = {Archiv der Pharmazie},
  year = {2023},
  volume = {356},
  number = {3},
  doi = {10.1002/ardp.202200465}
}
Kostenlos starten →